| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.CIR.0000016642.15031.34 |
| P698 | PubMed publication ID | 12021226 |
| P2093 | author name string | Richard Pacher | |
| Rudolf Berger | |||
| Martin Huelsman | |||
| Petra Moser | |||
| Brigitte Stanek | |||
| Anja Bojic | |||
| Karin Strecker | |||
| P433 | issue | 20 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heart failure | Q181754 |
| chronic heart failure | Q11829287 | ||
| P304 | page(s) | 2392-2397 | |
| P577 | publication date | 2002-05-01 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. | |
| P478 | volume | 105 |
| Q22306358 | 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines |
| Q48403487 | A change in N-terminal pro-brain natriuretic peptide is predictive of outcome in patients with advanced heart failure |
| Q44551633 | A prognostic index to predict long-term mortality in patients with mild to moderate chronic heart failure stabilised on angiotensin converting enzyme inhibitors |
| Q47850978 | A survey of coronary risk factors and B-type natriuretic peptide concentrations in cardiac nurses from Europe: do nurses still practice what they preach? |
| Q50769899 | Accumulation of risk markers predicts the incidence of sudden death in patients with chronic heart failure. |
| Q35724664 | Admission hypoxia-inducible factor 1α levels and in-hospital mortality in patients with acute decompensated heart failure |
| Q36229049 | Ambient temperature and biomarkers of heart failure: a repeated measures analysis |
| Q37374009 | Amino-terminal pro-B-type natriuretic peptide and high-sensitivity C-reactive protein as predictors of sudden cardiac death among women |
| Q50193224 | An Appraisal of Biomarker-Based Risk-Scoring Models in Chronic Heart Failure: Which One Is Best? |
| Q39689820 | Association between cardiac, renal, and hepatic biomarkers and outcomes in patients with acute heart failure |
| Q35554770 | Association of BNP and Troponin Levels with Outcome among Cardiac Resynchronization Therapy Recipients |
| Q37127236 | Association of diurnal blood pressure pattern with risk of hospitalization or death in men with heart failure |
| Q48234593 | B-Type Natriuretic Peptide Levels Predict Ventricular Arrhythmia Post Left Ventricular Assist Device Implantation |
| Q88631854 | B-Type Natriuretic Peptide Levels and Mortality in Patients With and Without Heart Failure |
| Q35987017 | B-type natriuretic peptide and its clinical implications in heart failure |
| Q37024202 | B-type natriuretic peptide as a biochemical marker of left ventricular diastolic function: assessment in asymptomatic patients 1 year after valve replacement for aortic stenosis. |
| Q48237778 | B-type natriuretic peptide in cardiovascular disease |
| Q35152072 | B-type natriuretic peptide in ischemic heart disease |
| Q48089433 | B-type natriuretic peptide levels in congenital heart disease |
| Q48402146 | B-type natriuretic peptide levels predict event-free survival in patients with implantable cardioverter defibrillators |
| Q34304406 | B-type natriuretic peptide-guided therapy for perioperative medicine? |
| Q42832965 | B-type natriuretic peptide: a role in selection and follow up of the implantable cardioverter-defibrillator patient? |
| Q35796786 | B-type natriuretic peptide: practical diagnostic use for evaluating ventricular dysfunction |
| Q34297057 | B-type natriuretic peptide: the level and the drug--partners in the diagnosis of congestive heart failure |
| Q37755096 | B-type natriuretic peptides in heart failure |
| Q82917977 | B-type natruiretic peptide levels stratify the risk for arrhythmia among implantable cardioverter defibrillator patients |
| Q35987052 | BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases |
| Q35570395 | BNP as discharge criteria for heart failure |
| Q37808764 | Biomarkers in Atrial Fibrillation, Ventricular Arrhythmias, and Sudden Cardiac Death |
| Q35805412 | Biomarkers in electrophysiology: role in arrhythmias and resynchronization therapy |
| Q37339808 | Biomarkers in heart failure: a clinical review. |
| Q35938537 | Biomarkers of cardiac disease |
| Q83429372 | Body mass index and rest myocardial perfusion defect predicts cardiac death in patients with chronic heart failure |
| Q36244209 | Brain natriuretic peptide and optimal management of heart failure |
| Q48234513 | Brain natriuretic peptide detects cardiac abnormalities in mass screening. |
| Q37605486 | Brain natriuretic peptide for the prediction of sudden cardiac death and ventricular arrhythmias: a meta-analysis |
| Q40533107 | Brain natriuretic peptide in the prediction of recurrence of angina pectoris. |
| Q36440968 | Brain natriuretic peptide levels and left ventricular functional recovery in a chronic heart failure population |
| Q40238774 | Brain type natriuretic peptide (BNP)-A marker of new millennium in diagnosis of congestive heart failure |
| Q37755067 | Can we use B-type natriuretic peptides to monitor patients with heart failure? |
| Q98184293 | Cardiac biomarkers in patients with prostate cancer and cardiovascular disease receiving gonadotrophin releasing hormone agonist vs antagonist |
| Q48103903 | Cardio-renal interaction: impact of renal function and anemia on the outcome of chronic heart failure |
| Q48840445 | Cardiovascular changes in children with coarctation of the aorta treated by endovascular stenting |
| Q36844771 | Change in N-terminal-pro-B-type-natriuretic-peptide and the risk of sudden death, stroke, myocardial infarction, and all-cause mortality in diabetic dialysis patients |
| Q39419960 | Changes in BNP and QTc for prediction of sudden death in heart failure |
| Q51247021 | Changes in the Cardiac GHSR1a-Ghrelin System Correlate With Myocardial Dysfunction in Diabetic Cardiomyopathy in Mice. |
| Q38979779 | Circulating annexin A5 predicts mortality in patients with heart failure |
| Q89861720 | Classic and Novel Biomarkers as Potential Predictors of Ventricular Arrhythmias and Sudden Cardiac Death |
| Q92661558 | Clinical Applications of Natriuretic Peptides in Heart Failure and Atrial Fibrillation |
| Q36836551 | Clinical findings, natriuretic peptides, and echocardiography: integrating tools to optimize heart failure management. |
| Q44856428 | Clinical use of markers of neurohormonal activation in heart failure |
| Q28208874 | Coagulation, inflammation and myocardial dysfunction in unstable coronary artery disease and the influence of glycoprotein IIb/IIIa inhibition and low molecular weight heparin |
| Q44621254 | Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failure |
| Q35580130 | Combination of drugs acting on the natriuretic system and the renin-angiotensin system in heart failure |
| Q36653533 | Comparison of the Degree of Exercise Tolerance in Children After Surgical Treatment of Complex Cardiac Defects, Assessed Using Ergospirometry and the Level of Brain Natriuretic Peptide. |
| Q48399609 | Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure |
| Q39174250 | Correlation between T-Wave Alternans and Cardiac Volume Status via Intrathoracic Impedance Measurements |
| Q38372438 | Denervated Myocardium Is Preferentially Associated With Sudden Cardiac Arrest in Ischemic Cardiomyopathy: A Pilot Competing Risks Analysis of Cause-Specific Mortality |
| Q45250859 | Determinants of B-type natriuretic peptide plasma levels in the chronic phase after heart transplantation |
| Q48493268 | Discordant regulation of CRP and NT-proBNP plasma levels after electrical cardioversion of persistent atrial fibrillation |
| Q48237656 | Does N-terminal pro-brain natriuretic peptide correlate with measured shunt fraction in children with septal defects? |
| Q55346961 | Echo and heart failure: when do people need an echo, and when do they need natriuretic peptides? |
| Q42141901 | Effect of omega-3 on brain natriuretic peptide and echocardiographic findings in heart failure: Double-blind placebo-controlled randomized trial |
| Q44455143 | Effects of caesarean section on serum levels of NT-proBNP. |
| Q33720841 | Effects of intracoronary injection of autologous bone marrow-derived stem cells on natriuretic peptides and inflammatory markers in patients with acute ST-elevation myocardial infarction. |
| Q34461640 | Effects of thoracic epidural analgesia on plasma cAMP and cGMP levels in patients with heart failure |
| Q86545201 | Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II |
| Q33155887 | Elevated B-type natriuretic peptide levels in patients with nonischemic cardiomyopathy predict occurrence of arrhythmic events |
| Q36102464 | Epidemiology and genetics of sudden cardiac death |
| Q36319305 | Exercise testing in adults after repair of aortic coarctation: evaluation of cardiopulmonary exercise capacity and B-type natriuretic protein levels. |
| Q44050644 | Gender aspects in clinical presentation and prognostication of chronic heart failure according to NT-proBNP and the Heart Failure Survival Score |
| Q35684262 | Genetic Polymorphisms as Risk Stratification Tool in Primary Preventive ICD Therapy |
| Q36997947 | Growth differentiation factor-15 and prognosis in acute respiratory distress syndrome: a retrospective cohort study |
| Q35675111 | Guidelines for acute decompensated heart failure treatment |
| Q38100647 | Heart failure biomarkers |
| Q43013810 | Hibernating myocardium: high or low risk? |
| Q92991345 | High N-Terminal proB-Type Natriuretic Peptide Indicates Elevated Risk of Death after Percutaneous Coronary Intervention Compared to Coronary Artery Bypass Surgery in Patients with Left Ventricular Dysfunction |
| Q33932889 | How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review |
| Q36234809 | Impact of Exhaled Breath Acetone in the Prognosis of Patients with Heart Failure with Reduced Ejection Fraction (HFrEF). One Year of Clinical Follow-up |
| Q48441711 | Impact of growth hormone (GH) treatment on circulating Nt-proBNP concentrations and on cardiac function in adult GH-deficient patients |
| Q48201512 | Impact of tricuspid regurgitation on survival in patients with chronic heart failure: unexpected findings of a long-term observational study |
| Q48881619 | Incidence of normal values of natriuretic peptides in patients with chronic heart failure and impact on survival: a direct comparison of N-terminal atrial natriuretic peptide, N-terminal brain natriuretic peptide and brain natriuretic peptide |
| Q50941959 | Inflammatory biomarkers are not predictive of intermediate-term risk of ventricular tachyarrhythmias in stable CHF patients. |
| Q52858483 | Is plasma N-BNP a good indicator of the functional reserve of failing hearts? The FRESH-BNP study. |
| Q41686228 | Korean Guidelines for Diagnosis and Management of Chronic Heart Failure. |
| Q92165320 | Left Ventricular Flow Analysis |
| Q30542622 | Left atrial enlargement and NT-proBNP as predictors of sudden cardiac death in patients with heart failure. |
| Q35561935 | Management of Acute Decompensated Heart Failure in the Emergency Department |
| Q42047460 | Management of asymptomatic severe aortic stenosis |
| Q46639330 | Mechanism of sudden cardiac death in pigs with viable chronically dysfunctional myocardium and ischemic cardiomyopathy |
| Q36070049 | Multiple biomarkers for risk prediction in chronic heart failure. |
| Q37929862 | Multivariate risk scores and patient outcomes in advanced heart failure. |
| Q48347865 | Myocardial performance after successful intervention for native aortic coarctation |
| Q83279662 | N-3 polyunsaturated fatty acids and statins in heart failure |
| Q49066781 | N-terminal brain natriuretic peptide is a more powerful predictor of mortality than endothelin-1, adrenomedullin and tumour necrosis factor-alpha in patients referred for consideration of cardiac transplantation |
| Q24607043 | N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease |
| Q56991478 | N-terminal pro-B-type natriuretic peptide and long-term mortality in non-ischaemic cardiomyopathy |
| Q37304997 | N-terminal pro-B-type natriuretic peptide is associated with sudden cardiac death risk: the Cardiovascular Health Study |
| Q48411276 | N-terminal pro-B-type natriuretic peptide-ratio predicts mortality after transcatheter aortic valve replacement |
| Q33918896 | N-terminal pro-brain natriuretic peptide and associated factors in the general working population: a baseline survey of the Uranosaki cohort study. |
| Q36921083 | N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction |
| Q48371711 | N-terminal prohormone brain natriuretic peptide-proBNP levels in ventricular arrhythmias in children |
| Q40528924 | NT-proBNP and BNP: biomarkers for heart failure management |
| Q64233573 | Natriuretic Peptides in Chronic Heart Failure |
| Q37626852 | Natriuretic peptides and cardiovascular damage in the metabolic syndrome: molecular mechanisms and clinical implications |
| Q42832904 | Natriuretic peptides as a prognostic marker and therapeutic target in heart failure |
| Q42997221 | Natriuretic peptides as markers of cardiovascular risk: the story continues |
| Q36983817 | Natriuretic peptides in cardiovascular diseases. |
| Q37399526 | Natriuretic peptides in the management of aortic stenosis |
| Q37157505 | Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. |
| Q37965174 | Neuro-endocrine regulation of blood pressure |
| Q49161329 | Neurohormonal risk stratification for sudden death and death owing to progressive heart failure in chronic heart failure |
| Q24798310 | Neurohumoral stimulation in type-2-diabetes as an emerging disease concept |
| Q48247579 | New York Heart Association class versus amino-terminal pro-B type natriuretic peptide for acute heart failure prognosis |
| Q45262893 | Outcome after device implantation in chronic heart failure is dependent on concomitant medical treatment. |
| Q35566132 | Outpatient management of heart failure |
| Q64969028 | Overexpression of miR-221 in sudden death with cardiac hypertrophy patients. |
| Q47987784 | Overexpression of the transcription factor Hand1 causes predisposition towards arrhythmia in mice. |
| Q36135133 | Palliation of heart failure |
| Q33353044 | Plasma biomarkers for prediction of sudden cardiac death: another piece of the risk stratification puzzle? |
| Q41048065 | Plasma growth hormone is a strong predictor of risk at 1 year in acute heart failure. |
| Q36389466 | Plasmatic B-type natriuretic peptide and C-reactive protein in hyperacute stroke as markers of CT-evidence of brain edema |
| Q35582942 | Predicting sudden death in patients with mild to moderate chronic heart failure |
| Q33152534 | Prediction and prevention of sudden cardiac death in heart failure |
| Q37496146 | Prediction of Atrial Fibrillation by B-type Natriuretic Peptide |
| Q42799896 | Prediction of long-term survival in chronic heart failure by multiple biomarker assessment: a 15-year prospective follow-up study |
| Q52584402 | Prediction of sudden death in elderly patients with heart failure. |
| Q36025668 | Prediction of sudden death in patients with mild-to-moderate chronic heart failure by using cardiac iodine-123 metaiodobenzylguanidine imaging |
| Q37353360 | Predictive value of admission N-terminal pro-B-type natriuretic peptide and renal function in older people hospitalized for dyspnoea. |
| Q36666782 | Predictive value of brain natriuretic peptides in patients on peritoneal dialysis: results from the ADEMEX trial |
| Q37020211 | Predictors of Sudden Cardiac Death in Doberman Pinschers with Dilated Cardiomyopathy |
| Q64069808 | Predictors of cardiac arrhythmic events in non coronary artery disease patients |
| Q35771323 | Preimplantation B-type natriuretic peptide concentration is an independent predictor of future appropriate implantable defibrillator therapies |
| Q35120874 | Prevention and management of chronic heart failure with electrical therapy |
| Q57396215 | Profile of microvolt T-wave alternans testing in 1003 patients hospitalized with heart failure |
| Q44273778 | Profiling B-type natriuretic peptide in a stable heart failure population: a valuable adjunct to care. |
| Q36105696 | Prognostic factors of mid-term clinical outcome in congestive heart failure patients discharged after acute decompensation |
| Q53541503 | Prognostic prediction in acute heart failure patients with extreme BNP values. |
| Q39677893 | Prognostic role of high-sensitivity C-reactive protein and B-type natriuretic peptide in implantable cardioverter-defibrillator patients |
| Q39840829 | Prognostic value of endothelial microparticles in patients with heart failure |
| Q37722784 | Prognostic value of increased carbohydrate antigen in patients with heart failure. |
| Q51842560 | Prognostic value of plasma midregional pro-adrenomedullin and C-terminal-pro-endothelin-1 in chronic heart failure outpatients. |
| Q37167684 | Prognostic value of resting pulmonary function in heart failure |
| Q51162819 | Psychometric testing of the Duke Activity Status Index in patients with heart failure. |
| Q46663954 | RETRACTED: Continuous intra- and postoperative thoracic epidural analgesia attenuates brain natriuretic peptide release after major abdominal surgery |
| Q42830406 | Raised B-type natriuretic peptide predicts implantable cardioverter-defibrillator therapy in patients with ischaemic cardiomyopathy. |
| Q35742271 | Recent advances in the diagnosis of heart failure |
| Q51068934 | Reduced diurnal variation of heart rate is associated with increased plasma B-type natriuretic peptide level in patients with atrial fibrillation. |
| Q51902181 | Renal dysfunction, as measured by the modification of diet in renal disease equations, and outcome in patients with advanced heart failure. |
| Q38089931 | Review on natriuretic peptides: where we are, where we are going |
| Q47546976 | Risk factors for heart failure hospitalizations among patients with atrial fibrillation. |
| Q44998997 | Risk stratification and prevention of sudden death in patients with heart failure |
| Q38376243 | Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus |
| Q37077973 | Role of galectin-3 and plasma B type-natriuretic peptide in predicting prognosis in discharged chronic heart failure patients |
| Q48116017 | Screening for left ventricular dysfunction using a hand-carried cardiac ultrasound device |
| Q37092258 | Serial monitoring of brain natriuretic peptide concentrations for drug therapy management in patients with chronic heart failure |
| Q36825438 | Serum B-type natriuretic peptide levels as a marker for anthracycline-induced cardiotoxicity |
| Q35174353 | Sleep-disordered breathing in heart failure: characteristics and implications |
| Q36239075 | Study designs and statistical analyses for biomarker research |
| Q63987361 | Sudden Cardiac Death (SCD) – risk stratification and prediction with molecular biomarkers |
| Q37238606 | Sudden cardiac death: epidemiology and risk factors. |
| Q35574016 | The Evolving Role of Nesiritide in Advanced or Decompensated Heart Failure |
| Q64942936 | The Predictive Value of Plasma Brain Natriuretic Peptide and Galectin-3 in Elderly Patients Admitted for Heart Failure. |
| Q41466512 | The Role of NT-proBNP in the Diagnosis of Ventricular Arrhythmias in Patients with Systemic Sclerosis |
| Q36237366 | The Role of Omega-3 Polyunsaturated Fatty Acids in Heart Failure: A Meta-Analysis of Randomised Controlled Trials |
| Q36944131 | The ability of heart failure specialists to accurately predict NT-proBNP levels based on clinical assessment and a previous NT-proBNP measurement |
| Q37369560 | The clinical utility of brain natriuretic peptide in paediatric left ventricular failure |
| Q36923138 | The cutting edge: membrane-anchored serine protease activities in the pericellular microenvironment |
| Q48540245 | The ease of use and reproducibility of the Alere™ Heart Check System: a comparison of patient and healthcare professional measurement of BNP. |
| Q36203083 | The emerging role of natriuretic peptides in the diagnosis and treatment of decompensated heart failure |
| Q36192931 | The neurohormonal axis and biochemical markers of heart failure |
| Q43009874 | The prediction of ICD therapy in multicenter automatic defibrillator implantation trial (MADIT) II like patients: a retrospective analysis. |
| Q36352015 | The prognostic value of anemia, right-heart catheterization and neurohormones in chronic heart failure |
| Q36058888 | The prognostic value of discordant T waves in lead aVR: A simple risk marker of sudden cardiac arrest in ischemic cardiomyopathy |
| Q87246873 | The relationship between BNP, NTproBNP and echocardiographic measurements of systemic blood flow in very preterm infants |
| Q34566491 | The role of B-type and other natriuretic peptides in health and disease |
| Q35626154 | The role of B-type natriuretic peptide in heart failure |
| Q42242419 | The usefulness of brain natriuretic peptide level in diagnosis and prognosis of patients admitted to critical care unit with shortness of breath |
| Q34541818 | Tools for risk stratification of sudden cardiac death: a review of the literature in different patient populations |
| Q64903654 | Towards a multi-marker prognostic strategy in acute heart failure: a role for GDF-15. |
| Q37023891 | Treatment of heart failure in adult congenital heart disease: a position paper of the Working Group of Grown-Up Congenital Heart Disease and the Heart Failure Association of the European Society of Cardiology |
| Q48509359 | Treatment of sleep apnea in congestive heart failure with a dental device: the effect on brain natriuretic peptide and quality of life |
| Q48227644 | Treatment of sleep-disordered breathing in heart failure: reduction of high ventricular wall stress should be a diagnostic and therapeutic target |
| Q36130511 | Understanding B-type natriuretic peptide and its role in diagnosing and monitoring congestive heart failure. |
| Q35566129 | Use of BNP levels in monitoring hospitalized heart failure patients with heart failure |
| Q37228387 | Use of natriuretic peptide assay in dyspnea |
| Q48313605 | Usefulness of in-hospital change in B-type natriuretic peptide levels in predicting long-term outcome in elderly patients admitted for decompensated heart failure |
| Q37109943 | Usefulness of the brain natriuretic peptide to atrial natriuretic peptide ratio in determining the severity of mitral regurgitation |
| Q46696940 | Utility of B-type natriuretic peptide in differentiating congestive heart failure from lung disease in pediatric patients with respiratory distress |
| Q35286926 | Utility of galectin-3 as a prognostic biomarker in heart failure: where do we stand? |
| Q42563345 | Utility of point-of-care testing of natriuretic peptides (brain natriuretic peptide and n-terminal pro-brain natriuretic peptide) in the emergency department |
| Q35588736 | Utilizing cardiac biomarkers to detect and prevent chemotherapy-induced cardiomyopathy |
| Q52581574 | What Is New in Heart Failure Management in 2017? Update on ACC/AHA Heart Failure Guidelines. |
| Q35549701 | What Price Support? Ventricular Assist Device Induced Systemic Response |
Search more.